Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
TRK inhibitor larotrectinib led to durable responses in people with colon, pancreatic, appendix, bile duct and liver cancers.
A novel drug that blocks multiple cancer-causing mutations shows promise, especially for combination therapy.
MRTX849 shrank tumors in half of lung cancer patients with a common but difficult to target mutation.
“It stands to reason that we should develop treatments specifically for appendix cancer.”
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.